Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

A team of researchers has developed gold nanoparticles (AuNPs) conjugated with trastuzumab as a possible cancer treatment. Published in Cancer Nanotechnology, the study focused on how these tiny ...

Glioblastoma (GBM) is one of the most common and aggressive primary brain tumors in adults, carrying an extremely poor ...

“Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression” “Inhibitors ...

Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies. Panelists discuss how resistance to EGFR tyrosine kinase ...

Dr Lovly concluded with her thoughts about the general challenges facing researchers addressing the problem of acquired resistance to targeted therapy in cancer: How do we effectively address the ...

A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with ...